INmune Bio

We want to congratulate lead author Betty Betty Rodrigues from Emory University, co-author INmune Bio's CJ Barnum and senior author Dr Malu Tansey from the University of Florida on their latest publication in the journal Alzheimer’s Research & Therapy. You can check out the full paper here:

Dr. Mark Lowdell, Co-Founder, Chief Scientific Officer and Chief Manufacturing Officer of INmune Bio Inc., shares how the experience gained in various trials to provide real treatment programs at scale, from the INB16 Lab. https://youtu.be/LMglBmCAfkk

In a study published in Cell, Mount Sinai researchers found that fasting may reduce inflammation and improves chronic inflammatory diseases without affecting the immune system's response to acute infections. https://medicalxpress.com//2019-08-fasting-inflammation-ch

Individuals who have a first-degree relative (parent, sibling, or child) with blood cancer have a higher likelihood of being diagnosed with the disease, and this risk is higher for that of some solid tumors. https://www.medscape.com/viewarticle/917931

INB03 is a protein biologic that could have many beneficial effects in patients with cancer. Our initial focus is on its ability to inhibit proliferation and function of Myeloid-Derived Suppressor Cells (MDSC). By preventing the proliferation and function of MDSC, we believe patients will have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy. https://www.inmunebio.com/index.php//science/inb03/overview

Want to stay on top of the latest INmune Bio news? Sign up for our newsletter today: https://www.inmunebio.com/index.php/en/contact-2/subscribe

Anxiety complicates life for dementia patients and their caregivers. https://www.washingtonpost.com//ab53170a-92bc-11e9-b58a-a6

Three carefully designed, well-executed, and fully resourced trials targeting amyloid protein in the brain as the cause of Alzheimer’s disease have failed. It’s long past time to take a new approach to this mind-robbing disease. https://www.statnews.com//amyloid-failures-new-tack-treat/

The peer-reviewed open access scientific journal PLOS ONE has published an article summarizing the different effects between NK cell activation in response to tumor cells and cytokine-mediated activation. https://www.statnews.com//alzheimers-artificial-intellig/

Further to INmune Bio's Chief Scientific Officer and Chief Manufacturing Officer Prof. Mark Lowdell's work with NK cells, this paper highlights that in a large number of patients, NK cells must be functional to clear residual disease in AML. https://www.nature.com/articles/s41586-019-1410-1

INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. https://immuno-oncologynews.com//immune-bio-early-results/

German and Canadian scientists have built a three dimensional map of the human brain to help in the development of new treatments for neurological disorders like Alzheimer's and Parkinson's disease. https://www.scientificamerican.com//3d-human-brain-map-po/

For years, Alzheimer's researchers have been guided by one leading theory that getting rid of a buildup of a sticky protein called amyloid would ease the mind-robbing disease. Yet drug after drug has failed. They might clear out the gunk, but they’re not stopping Alzheimer’s inevitable worsening. The new mantra: diversify. https://www.washingtonpost.com//921fbcf4-d3dd-11e9-8924-1d